Clinical and demographic predictors of attenuated LDL-C response to PCSK9 inhibition with bococizumab: Insights from the SPIRE trials.

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

Sign in for access options

About the speaker

Doctor Hasan Siddiqi

Brigham and Women's Hospital, Boston (United States of America)

13 More presentations in this session

Presentation thumbnail

Reduction in high-sensitivity C-reactive protein by pitavastatin was associated with improved outcomes in Japanese patients with stable coronary artery disease: results from REAL-CAD study

Doctor H. Iwata (Tokyo, JP)

Presentation thumbnail

The association of Lp(a) levels and cardiovascular disease in adult patients with familial hypercholesterolemia: analysis from the HELLAS-FH registry

Professor E. Liberopoulos (Athens, GR)

Abstract Slides

Presentation thumbnail

Oxidized phospholipids on apolipoprotein B-100 among black US adults with and without PCSK9 loss-of-function variants

Doctor M. Mefford (Birmingham, US)

Presentation thumbnail

HDL-C and all-cause mortality in a high-risk population: impact of LDL-C

Doctor D. Dhindsa (Atlanta, US)

Presentation thumbnail

Children with familial hypercholesterolemia: lipid profile, treatment and evaluation of different formulas for calculating low-density lipoprotein cholesterol: an analysis from the HELLAS-FH registry

Professor E. Liberopoulos (Athens, GR)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 6 - Lipids

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Webinar

Unmet needs in lipid management: treatment goals and how to achieve them

Webinar

Risk assessment and lipid management in primary prevention

Webinar

New trial evidence in the field of lipid management

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources